- Home
- ATNM vs NSPR Comparison
ATNM vs NSPR Comparison
Compare ATNM & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- NSPR
- Stock Information
- Founded
- ATNM 2000
- NSPR 2005
- Country
- ATNM United States
- NSPR Israel
- Employees
- ATNM N/A
- NSPR N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- NSPR Medical/Dental Instruments
- Sector
- ATNM Health Care
- NSPR Health Care
- Exchange
- ATNM Nasdaq
- NSPR Nasdaq
- Market Cap
- ATNM 56.5M
- NSPR 63.0M
- IPO Year
- ATNM N/A
- NSPR N/A
- Fundamental
- Price
- ATNM $1.17
- NSPR $3.19
- Analyst Decision
- ATNM Strong Buy
- NSPR Strong Buy
- Analyst Count
- ATNM 4
- NSPR 2
- Target Price
- ATNM $8.75
- NSPR $4.75
- AVG Volume (30 Days)
- ATNM 167.7K
- NSPR 52.2K
- Earning Date
- ATNM 03-28-2025
- NSPR 03-05-2025
- Dividend Yield
- ATNM N/A
- NSPR N/A
- EPS Growth
- ATNM N/A
- NSPR N/A
- EPS
- ATNM N/A
- NSPR N/A
- Revenue
- ATNM $81,000.00
- NSPR $6,821,000.00
- Revenue This Year
- ATNM $138.42
- NSPR $13.36
- Revenue Next Year
- ATNM $16,957.05
- NSPR $49.64
- P/E Ratio
- ATNM N/A
- NSPR N/A
- Revenue Growth
- ATNM N/A
- NSPR 24.70
- 52 Week Low
- ATNM $1.07
- NSPR $1.81
- 52 Week High
- ATNM $10.24
- NSPR $3.42
- Technical
- Relative Strength Index (RSI)
- ATNM 46.97
- NSPR 63.51
- Support Level
- ATNM $1.15
- NSPR $2.60
- Resistance Level
- ATNM $1.29
- NSPR $3.11
- Average True Range (ATR)
- ATNM 0.07
- NSPR 0.28
- MACD
- ATNM 0.01
- NSPR 0.05
- Stochastic Oscillator
- ATNM 46.51
- NSPR 87.15
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.